TXNRD2 and prostate cancer: MiR-17-3p elevated ROS levels by inhibiting three primary mitochondrial antioxidants, MnSOD, glutathione peroxidase 2 (Gpx2) and thioredoxin reductase 2 (TrxR2), remarkably strengthening the sensitivity of prostate cancer cells to IR [100].